Actively Recruiting
EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications
Led by University of Illinois at Chicago · Updated on 2025-07-25
70
Participants Needed
1
Research Sites
31 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.
CONDITIONS
Official Title
EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Providing informed consent to participate in the study.
- Aged between 22 and 85 years old.
- Diagnosis of Opioid Use Disorder (OUD) for more than 6 months as defined by DSM-5 with a positive urine toxicology screen and current craving (for OUD subjects).
- Lives in the immediate area with no plans to relocate.
- Age-matched controls without OUD are also eligible if they meet age and location criteria.
You will not qualify if you...
- Recently started on antiepileptic drug therapy.
- Ingestion of poppy seeds or herbal teas containing Papaveris fructus (may cause positive opiate tests).
- History of neurological disorders such as stroke, brain tumors, or epilepsy.
- History of unexplained fainting spells.
- History of head injury causing more than momentary loss of consciousness.
- History of brain surgery.
- Suffering from severe depression.
- Presence of active malignancy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical & Imaging Research Outcomes Lab
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
A
Aksarapak Hengyotmark, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here